Wholly-owned Rhone-Poulenc subsidiary Pasteur Merieux Connaught, a world leader in vaccine development and production, presented its new strategy and corporate image, with a single name for all its affiliates, in Paris, France, last week.
Chairman and chief executive Jean-Jacques Bertrand said that since 1993, PMC has seen important changes - concentrating on vaccines activity, and its partnership with Merck & Co - which require the drawing up of a new strategy based on:
- strengthening the innovation potential to optimize existing vaccines and develop new ones for extending vaccination coverage throughout the world;
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze